TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01983579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraocular anti-VEGF injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraocular anti-VEGF injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraocular anti-VEGF injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Study: NCT01531387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
Study: NCT03569332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alarm
Description: 1. Alarm is provided from 9am to 9pm.~2. Alarm is active every 50 minutes if the exercise goal(10 times/hour) hasn't satisfied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse's dashboard
Description: 1. Wireless data transmission system~2. The practicing rate of participants on study group is sent to Nurse's Dashboard.~3. It is only to display.
Study: NCT04391387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prone position
Description: a position with the patient lying face down with arms bent comfortably at the elbow and padded with the armboards positioned forward

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prone position
Description: a position with the patient lying face down with arms bent comfortably at the elbow and padded with the armboards positioned forward
Study: NCT03532620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin Calcium
Description: In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled.
Study: NCT04166838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 UCARTcells
Description: This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 \^ 6 cells/kg,3 × 10 \^ 6 cells/kg,5 × 10 \^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
Study: NCT00047112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02454855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg.
Study: NCT02819687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02921087

Intervention type: DEVICE
Group type: OTHER
Intervention: Test Daily Disposable Soft Contact Lenses
Description: Worn daily for 7 +/- 2 days

Intervention type: DEVICE
Group type: OTHER
Intervention: Test Daily Disposable Soft Contact Lenses
Description: Worn daily for 7 +/- 2 days

Intervention type: DEVICE
Group type: OTHER
Intervention: Control Daily Disposable Soft Contact Lenses
Description: Worn daily for 7 +/- 2 days

Intervention type: DEVICE
Group type: OTHER
Intervention: Control Daily Disposable Soft Contact Lenses
Description: Worn daily for 7 +/- 2 days
Study: NCT01848132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: intravenous, 375 mg/m2, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab: intravenous, 375 mg/m2, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: intravenous, 750 mg/m2, day 1
Study: NCT02484482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
Study: NCT06446791

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mehri Turki Surgical Technique of the Webbed Neck
Description: The incision was made at the junction of the hairless skin and the hairy skin from the mastoid up to the acromion. A subcutaneous undermining allows direct visual control to excise the fibrotic band. Then the hairy skin with a triangular shape was excised. The closure of the defect was done after undermining an anterior cervical flap which was translated in a posterosuperior direction. Z plasty was performed in front of the acromion to prevent scar contracture. Surgical scars are concealed in the hairline which was well placed. The same procedure is done at the same surgical field on the other side to achieve perfect symmetry.
Study: NCT02505113

Intervention type: DRUG
Intervention: Montelukast
Description: Montelukast (10mg, q.d., p.o.)
Study: NCT03701919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin pyloroplasty
Description: Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
Study: NCT02027324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol group
Description: 2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
Study: NCT03701919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline pyloric injection
Description: Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
Study: NCT01160913

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous wound infusion
Study: NCT02027324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Group
Description: 10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
Study: NCT00495794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-based intervention
Description: Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
Study: NCT01960036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body-oriented Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Womens Health Education
Study: NCT00749489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
Study: NCT02254616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy with tDCS
Description: The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy with sham-tDCS
Description: The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy
Description: The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
Study: NCT01160913

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous wound
Study: NCT03659136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Intravenous infusion
Study: NCT02454855

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
Study: NCT00492440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-7
Study: NCT03659136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus
Description: Tablet
Study: NCT00492440

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study: NCT02254616

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
Study: NCT01361724

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical therapy
Description: Physical therapy program for people with PD--one on one with a PT

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Exercise Class
Description: The participant will be in an exercise class for 3 days a week for 4 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Program
Description: The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
Study: NCT00492440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study: NCT02404324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription of spectacles
Description: All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
Study: NCT02020681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: Self-assembling peptide, biomimetic re-mineralisation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation of Curodont Repair without the peptide P11-4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Single application on day D90

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Single application on day D90
Study: NCT02013999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality program for upper extremity rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard occupational therapy
Study: NCT01359865

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Lumbar Plexus Block
Description: lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at \<0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
Study: NCT03917394

Intervention type: DRUG
Intervention: rHuEPO
Description: rHuEPO was administrated daily with 10000 IU or 20000 IU

Intervention type: DRUG
Intervention: rHuEPO
Description: rHuEPO was administrated daily with 10000 IU or 20000 IU

Intervention type: DRUG
Intervention: Iron sucrose
Description: Iron sucrose was administrated daily with 100mg or 200mg

Intervention type: DRUG
Intervention: Iron sucrose
Description: Iron sucrose was administrated daily with 100mg or 200mg
Study: NCT03092141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Study: NCT03950505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
Description: All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5\~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
Study: NCT01558206

Intervention type: OTHER
Intervention: Pulmonary artery CT Angiography
Description: Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
Study: NCT00492440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT04248530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: DENEX catheter is a device to treat resistant hypertension which delivers high-frequency energy through the three electrodes connected to the catheter in order to cauterize sympathetic nerve bundle.
Study: NCT00727012

Intervention type: DEVICE
Group type: OTHER
Intervention: mitral valve repair (SJM® Rigid Saddle Ring)
Description: mitral valve repair due to mitral degenerative or functional disease
Study: NCT01558206

Intervention type: OTHER
Intervention: Emergency Bedside Ultrasonography of chest
Description: Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
Study: NCT02398643

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Education (PE)
Description: Patients enrolled in PE will undergo focused education sessions following discharge from hospital.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients enrolled in usual care will receive general education sessions following discharge from hospital.
Study: NCT04686396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix
Description: Demineralized bone matrix
Study: NCT02211417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral DS107

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01810302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride
Description: Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative-free normal saline
Description: Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
Study: NCT01458691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injection into the glenohumeral joint
Description: * Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic PRP injection into the glenohumeral joint
Description: * Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance.
Study: NCT04046289

Intervention type: DIETARY_SUPPLEMENT
Intervention: Low Calcium Milk
Description: 50 mg calcium/day
Study: NCT00005828

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract
Study: NCT01969903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex injection
Study: NCT03659136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Tablet
Study: NCT01848132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide: intravenous, 750 mg/m2, day 1
Study: NCT03659136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Tablet
Study: NCT04255641

Intervention type: OTHER
Intervention: time lapse analysis
Description: grading of the embryos before freezing using time lapse/
Study: NCT03167528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnosis
Study: NCT04046289

Intervention type: DIETARY_SUPPLEMENT
Intervention: Regular Calcium Milk
Description: 400 mg/day

Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotic 1
Description: regular calcium milk + probiotic

Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotic 2
Description: regular calcium milk + probiotic
Study: NCT03515499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication device monitoring and reminders
Description: Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
Study: NCT01848132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Adriamycin:intravenous, 50 mg/m2, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Adriamycin:intravenous, 50 mg/m2, day 1
Study: NCT03167528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic gymnastics
Description: holistic gymnastics

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: TENS
Study: NCT02935790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-241
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: infusion
Study: NCT03167528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sophrology
Description: Sophrology
Study: NCT03263416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dedicated and coordinated follow-up
Description: * Coordinated follow-up performed by a dedicated nurse with consultations (before treatment initiation and during treatment) and a telephone follow-up during treatment period~* Pharmaceutical conciliation before treatment initiation made by the Center Pharmacist~* Completion of QLQ-C30 and GIRERD questionnaires